Wird geladen...
Raltitrexed Inhibits HepG2 Cell Proliferation via G(0)/G(1) Cell Cycle Arrest
Raltitrexed (RTX) is an antimetabolite drug used as a chemotherapeutic agent for treating colorectal cancer, malignant mesothelioma, and gastric cancer. The antitumor capacity of RTX is attributed to its inhibitory activity on thymidylate synthase (TS), a key enzyme in the synthesis of DNA precursor...
Gespeichert in:
| Veröffentlicht in: | Oncol Res |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Cognizant Communication Corporation
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7838684/ https://ncbi.nlm.nih.gov/pubmed/27098147 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3727/096504016X14562725373671 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|